DEF: Palatin Technologies Seeks Shareholder Approval for Reverse Stock Split, Equity Plan Expansion, and Warrant Issuances Amidst Delisting Appeal

Palatin Technologies, Inc. is seeking shareholder approval for a reverse stock split to facilitate a potential Nasdaq uplisting, an increase in its equity incentive plan shares, and the issuance of common stock upon the exercise of recently issued warrants, following its delisting from NYSE American.

Summary

• An Annual Meeting of Stockholders will be held virtually on Friday, July 25, 2025, at 9:00 a.m. Eastern Time, with a record date of June 20, 2025.
• The Board of Directors recommends voting FOR all nine proposals, including the election of four directors, a reverse stock split, ratification of KPMG LLP as independent auditor, three warrant issuances, an increase in the equity incentive plan, and advisory votes on executive compensation frequency and compensation itself.
• A reverse stock split at a ratio of 1-for-50 to 1-for-100 is proposed to potentially meet Nasdaq's minimum bid price requirement of $4.00 per share, following the suspension of trading on NYSE American on May 7, 2025, due to low selling price.
• The company's common stock currently trades on the OTCQB Venture Market (OTCQB: PTNT) at $0.107 per share as of June 16, 2025.
• Shareholder approval is sought for the issuance of 1,624,201 shares from Series B Warrants (exercise price $1.88), 1,953,839 shares from Series D Warrants (exercise price $0.875), and 6,181,818 shares from Series I Warrants (exercise price $0.11).
• An increase of 3,000,000 shares (from 4,300,000 to 7,300,000) is requested for the 2011 Stock Incentive Plan, with only 232,388 shares currently available for future grants as of June 20, 2025.
• Fiscal Year 2024 financial highlights include revenue of $4,490,090 (down from $4,853,678 in FY23), a net loss of $(29.7) million (up from $(24.0) million in FY23), and cash and cash equivalents of $9.5 million (up from $8.0 million in FY23).
• Key pipeline updates include positive topline Phase 2 results for the obesity program (bremelanotide with tirzepatide) showing increased weight loss, completed Phase 3 for the ocular program (PL9643 for DED) with topline results in Q1 2024, and positive topline Phase 2 results for the ulcerative colitis program (PL8177) with one-third of patients achieving clinical remission.

Sentiment

Score: 4

Explanation: While there are positive clinical updates and an increase in cash, the delisting from NYSE American, increased net loss, and declining revenue indicate significant operational and market challenges. The proposed reverse stock split and warrant issuances, while necessary for future capital and listing, also highlight the company's precarious financial position and potential for further dilution.

Positives

• Positive topline Phase 2 results for the obesity program (co-administration of bremelanotide with tirzepatide) demonstrated increased weight loss over tirzepatide alone.
• Topline results from the first Phase 3 clinical trial for PL9643 (dry eye disease) were announced in the first quarter of calendar year 2024.
• Positive topline Phase 2 results for PL8177 (ulcerative colitis) showed one-third of patients achieving clinical remission, while the placebo group saw no clinical remission.
• Cash and cash equivalents increased to $9.5 million at June 30, 2024, from $8.0 million at June 30, 2023.
• The company has adopted a clawback policy and eliminated golden parachute excise tax gross-up provisions in executive employment agreements in response to stockholder feedback.
• The executive compensation program is designed with a significant portion of compensation at risk and long-term equity incentives being no less than base salaries, with at least half being performance-based.

Negatives

• The company's common stock was suspended from trading on the NYSE American on May 7, 2025, and subsequently delisted due to a low selling price, now trading on the OTCQB Venture Market.
• Revenue decreased to $4,490,090 for fiscal 2024 from $4,853,678 for fiscal 2023.
• Net loss increased to $(29.7) million for fiscal 2024 from $(24.0) million for fiscal 2023.
• The proposed reverse stock split carries risks, including no guarantee of a proportional increase in share price, attracting new investors, or maintaining the required listing price.
• The issuance of shares upon warrant exercises will have a dilutive effect on existing stockholders' percentage ownership, book value per share, and future earnings per share.

Risks

• The proposed reverse stock split may not result in an increase in the per share price of Common Stock proportional to the reduction in the number of shares outstanding.
• There is no assurance that a reverse stock split will result in a per share price that will attract brokers and investors who do not trade in lower-priced stocks.
• There is no assurance that a reverse stock split will result in a per share price that will increase the company's ability to attract and retain employees.
• There is no assurance that the market price per share will achieve and maintain the stock price required for an uplisting to a national securities exchange.
• If a reverse stock split is effected and the market price of the Common Stock declines, the percentage decline as an absolute number and as a percentage of the overall market capitalization may be greater than would occur in the absence of a reverse stock split.
• The liquidity of the Common Stock could be adversely affected by the reduced number of shares outstanding after a reverse stock split.
• The increased proportion of unissued authorized shares to issued shares from the reverse stock split could, under certain circumstances, have an anti-takeover effect by permitting issuances that would dilute the stock ownership of a person seeking to effect a change in the composition of the Board or contemplating a tender offer.
• The issuance of shares upon exercise of Series B, Series D, and Series I Warrants will have a dilutive effect on other stockholders, reducing their percentage ownership, book value per share, and future earnings per share.

Future Outlook

The company aims to uplist its common stock to a national securities exchange like Nasdaq or NYSE American by effecting a reverse stock split to meet minimum bid price requirements. It plans to continue developing its MCr product candidates, including advancing its obesity, ocular, and ulcerative colitis programs, and actively seeks strategic alliances and partnerships to facilitate product development and commercialization. The company expects the proposed increase in its equity incentive plan shares to meet its equity compensation needs for at least the next year.

Management Comments

• Our board of directors recommends that you vote For each of the nominees for director in Item 1 and For Item 2 (approval of an amendment to our Restated Certificate of Incorporation to effect a reverse stock split), Item 3 (ratification of appointment of KPMG LLP as our independent registered public accounting firm), Item 4 (approval of the issuance of shares of our common stock upon exercise of certain Series B warrants), Item 5 (approval of the issuance of shares of our common stock upon exercise of certain Series D warrants), Item 6 (approval of the issuance of shares of our common stock upon exercise of certain Series I warrants), Item 7 (approval of an amendment to our equity incentive plan), Item 8 (approval, on an advisory, non-binding basis, of the frequency of future advisory votes on the compensation of our named executive officers) and Item 9 (approval, on an advisory, non-binding basis, of the compensation of our named executive officers).
• Our Board believes that having our shares listed and trading on a national exchange, such as Nasdaq or NYSE American, would be beneficial to both the Company and its stockholders.
• We believe that having our shares listed and trading on a national exchange, such as Nasdaq or NYSE American, will help attract institutional investors with minimum trading price and other requirements, will assist in our capital-raising efforts should they be needed in the future to support the Company’s growth plans by making our Common Stock more attractive to a broader range of investors, will remove restrictions that currently prohibit many investors from investing in companies whose shares are not traded on a national exchange, and that a national exchange’s financial and governance requirements will enhance the Company’s profile to potential investors.
• If successful, the Company’s stockholders will also benefit from expanded awareness by inclusion in a number of indexes that are tracked by buy-side institutions and that will increase the likelihood of analyst coverage.
• The Board believes that an increased stock price may also improve the marketability and liquidity of our Common Stock.
• The Board believes that the potential increase in stock price may reduce the risk of market manipulation of our Common Stock, which we believe is enhanced when our stock trades below $1.00 per share.
• The Board believes that it will not be able to continue carrying out the purposes of the 2011 Stock Incentive Plan for the need fiscal year unless additional stock becomes available for issuance.
• We expect that the shares authorized for issuance under the 2011 Stock Incentive Plan will meet our equity compensation needs for at least the next year.
• The Board considers equity-based compensation an essential tool to attract, motivate and retain our officers, key employees and directors and to align their interests with the interests of our stockholders.
• If we are unable to grant equity awards in the future, we may be required to increase the cash component of our compensation mix, which would inhibit our ability to meet our compensation objectives, including aligning our executives and directors interests with the interests of our stockholders and motivating our executives over a long-term horizon.
• We believe that NEO compensation for the fiscal year ended June 30, 2024, was effective in retaining and motivating our NEOs to work toward our annual and long-term goals, and well within the range of normal practices for companies of our size and in our industry.

Industry Context

Palatin Technologies operates in the biopharmaceutical sector, focusing on melanocortin peptide receptor systems. The company's efforts to uplist to Nasdaq and its recent delisting from NYSE American highlight the challenges faced by smaller biotech firms in maintaining exchange listings due to low stock prices, a common issue in the volatile biotech market. Its pipeline development in obesity, ocular conditions, and ulcerative colitis aligns with significant unmet medical needs, reflecting broader industry trends towards addressing chronic and complex diseases. The company's strategy of seeking strategic alliances and partnerships is typical for development-stage biopharmaceutical companies aiming to leverage external resources for clinical development and commercialization.

Comparison to Industry Standards

• The company's delisting from NYSE American due to low selling price and subsequent trading on OTCQB is a common challenge for small-cap biopharmaceutical companies, many of which struggle to maintain minimum bid price requirements for major exchanges like Nasdaq ($4.00 minimum bid price) or NYSE American.
• The proposed reverse stock split is a standard corporate action taken by companies, such as Athersys, Inc. or Savara Inc. (from their peer group), to increase their per-share price to meet listing requirements or improve marketability, though success is not guaranteed.
• The company's burn rate for equity awards (average 7.89% over 2022-2024) and overhang (14.2% with proposed increase) are metrics typically evaluated against industry peers to assess dilution and compensation practices. While specific benchmarks vary by sub-sector and stage, these figures are generally within acceptable ranges for development-stage biotech companies that rely heavily on equity compensation.
• The company's executive compensation practices, including a significant portion of compensation at risk, performance-based long-term incentives (50%), and the adoption of a clawback policy, align with evolving corporate governance best practices and investor expectations, as seen in larger pharmaceutical companies like Johnson & Johnson or smaller biotech firms like CorMedix Inc. or Oragenics, Inc. (companies whose boards share members with Palatin).
• The company's pipeline development in obesity (co-administration of bremelanotide with tirzepatide), dry eye disease (PL9643), and ulcerative colitis (PL8177) addresses large market opportunities, similar to strategic focuses of other biopharmaceutical companies in their peer group like Eton Pharmaceuticals, Inc. or Paratek Pharmaceuticals, Inc., which also target specific therapeutic areas.

Corporate Governance

Related Party Transactions

• Issuance of 3,400 shares of Series D Convertible Preferred Stock and Series I Warrants to purchase up to 6,181,818 shares of Common Stock to certain officers and directors (Carl Spana, Stephen T. Wills, John K.A. Prendergast, and Alan W. Dunton) on June 10, 2025, with closing on June 13, 2025.

Stakeholder Impact

• Shareholders: Potential for significant dilution from warrant exercises and the reverse stock split. The reverse stock split aims to improve marketability and potentially enable uplisting to Nasdaq, which could benefit institutional investors and increase analyst coverage. However, there's a risk the stock price may not sustain the increase. The say-on-pay vote and executive compensation practices are designed to align management interests with shareholders.
• Employees: The proposed increase in the 2011 Stock Incentive Plan shares is intended to attract, motivate, and retain key employees through equity compensation, aligning their interests with the company's long-term success.
• Customers: The continued development of product candidates in obesity, dry eye disease, and ulcerative colitis aims to address unmet medical needs, potentially benefiting future patients.
• Creditors: The company's financial health, including its cash position and ability to raise capital, directly impacts its ability to meet obligations to creditors. The capital raises through warrant exercises and potential future financing efforts are relevant.
• Management: Executive compensation is tied to corporate performance and individual achievements, with a significant portion at risk and long-term incentives. The proposed equity plan expansion provides tools for continued incentive alignment.

Next Steps

• Hold virtual Annual Meeting of Stockholders on July 25, 2025, to vote on proposals.
• Board to determine exact ratio and timing of reverse stock split if approved by stockholders.
• Company to file amendment for reverse stock split with the Secretary of State if approved and listing requirements are met.
• Continue appealing the NYSE American delisting decision.
• Actively engage in discussions with potential partners and licensees for ocular conditions.
• Report topline results for the ulcerative colitis program (PL8177) later this quarter.
• Call stockholder meetings every 90 days to seek approval for warrant issuances if not obtained at the upcoming annual meeting.
• Conduct a compensation peer group analysis every two years, with a revised peer group anticipated for awards in June 2025 for fiscal year ending June 30, 2026.

Key Dates

Recommendation

Keywords

Palatin Technologies, PTNT, SEC Filing, Proxy Statement, DEF 14A, Reverse Stock Split, Nasdaq Uplisting, NYSE American Delisting, Equity Incentive Plan, Warrants, Biopharmaceutical, Melanocortin Receptor System, Obesity Treatment, Dry Eye Disease, Ulcerative Colitis, Clinical Trials, Corporate Governance, Executive Compensation, Shareholder Meeting, Dilution, Capital Raise